Zenas BioPharma (ZBIO) EBIT (2023 - 2026)

Zenas BioPharma's EBIT history runs 4 years deep, the most recent figure standing at -$77.4 million for Q1 2026.

• In Q1 2026, EBIT fell 107.21% year-over-year to -$77.4 million; the TTM figure through Mar 2026 stood at -$423.1 million (down 143.65% YoY), while the FY2025 annual figure was -$383.1 million, down 133.73% from the prior year.
• EBIT was -$77.4 million for Q1 2026 at Zenas BioPharma, up from -$238.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $35.6 million in Q3 2023 to a low of -$238.0 million in Q4 2025.
• Historically, EBIT has averaged -$55.8 million across 4 years, with a median of -$41.0 million in 2024.
• Biggest YoY gain for EBIT was 28.29% in 2025; the steepest drop was 327.85% in 2025.
• A 4-year view of EBIT shows it stood at -$24.8 million in 2023, then sank by 124.48% to -$55.6 million in 2024, then plunged by 327.85% to -$238.0 million in 2025, then jumped by 67.5% to -$77.4 million in 2026.
• The last three EBIT figures came in at -$77.4 million (Q1 2026), -$238.0 million (Q4 2025), and -$52.6 million (Q3 2025), per Business Quant data.